Kollitab™ DC 87 L: All-in-One Tableting Solution
A novel direct compression co-processed excipient
On Direct Compression
Known for their convenience, tablets are the most popular solid oral dosage form preferred by both patients and manufacturers alike. Out of the commonly utilised main processing methodologies, direct compression (DC) is favoured. However, DC formulations typically require multiple excipients to fulfil flowability, compressibility, disintegration, and lubrication requirements. Co-processed excipients, which combine two or more functional materials into a single ingredient, can be used to overcome these formulation challenges through their enhancement of the resulting material’s performance and processability.
Features & Benefits
What makes Kollitab™ DC 87 L the better blend?
Enables high process consistency with reduced weight variability
High hardness at low compression force
Minimises tablet defects while reducing machine stress and punch damage
Fast disintegration time
Decreases impact on drug dissolution
Kollitab™ DC 87 L Composition
MDE: 4384 mg for tablets
(Ph. Eur., USP/NF, JP), (~87%)